The Cedar Rapids oncology Project CC0P has provided an active cancer research program to eastern Iowa and western Illinois since 1965. CROP is comprised in Cedar Rapids, Iowa, of Mercy Medical center, St. Luke's Hospital, the Hall Radiation Center and Oncology Associates; and in Moline, Illinois, of United Medical Center and the oncology section of Medical Arts Associates. These components are the primary providers of specialized cancer care to these communities. All medical oncologists and radiotherapists practicing in Moline and Cedar Rapids are participants with this research effort. Modern, sophisticated and comprehensive diagnostic and treatment facilities are available. The components of CROP provide cancer care to a population base of 500,000 people in eastern Iowa and western Illinois. It is estimated that CROP sees 80% of newly diagnosed cancer patients from this region for an annual total of 1,500 to 1,600 patients. Approximately 40% of patients accrued to CROP studies are from rural areas. Expertise has been gained meeting the special needs and problems of providing cancer research to this large rural population. CROP has functioned since 1985 and the continuity of this program, with experienced key personnel, has allowed for steady expansion and exceptional quality control. There have been no major violations and extremely low rates of ineligibility (1.3%) have been maintained since 1985 covering over 1,000 study entries. Internal as well as external quality assurance measures have been developed and carefully tested. Quality control is further validated by results of a recent audit conducted by its research bases. CROP identifies NCCTG as its primary research base, with EC0G and NSABP as secondary research bases. These multiple bases provide the availability of a comprehensive cancer treatment and control research program appropriate for community participants. Participation with NSABP has allowed access to the Breast Cancer Prevention Trial (BCPT). Cancer treatment and cancer control accrual has steadily increased with CC0P participation. In 1988, before CC0P funding, 75 treatment patients were entered, and this has increased in 1991 to 133 cancer treatment entries. Cancer control accrual has also increased with activation of the BCPT. After two months of participation with the BCPT, 10 patients have been randomized and 87 women have given signed consent and are in the process of being placed on study. It is expected that the CCOP will exceed 50 cancer control credits in 1992. A detailed organizational structure arid data management plan is submitted. These systems are operational and have proven effective through years of research participation. CROP has documented its ability to provide an effective multi-disciplinary cancer research program. Continuation of CROP as a funded CC0P will permit greater and more productive efforts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA052352-06
Application #
2094705
Study Section
Special Emphasis Panel (SRC (70))
Project Start
1990-09-15
Project End
1998-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
6
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Cedar Rapids Oncology Project
Department
Type
DUNS #
186618497
City
Cedar Rapids
State
IA
Country
United States
Zip Code
52403
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9
Galanis, Evanthia; Anderson, S Keith; Lafky, Jackie M et al. (2013) Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. Clin Cancer Res 19:4816-23
Brown, Lindsay C; Atherton, Pamela J; Neben-Wittich, Michelle A et al. (2013) Assessment of long-term rectal function in patients who received pelvic radiotherapy: a pooled North Central Cancer Treatment Group trial analysis, N09C1. Support Care Cancer 21:2869-77
Kottschade, Lisa A; Suman, Vera J; Perez, Domingo G et al. (2013) A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Cancer 119:586-92
Lavoie Smith, Ellen M; Barton, Debra L; Qin, Rui et al. (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787-99

Showing the most recent 10 out of 120 publications